Novo Nordisk says weight-loss drug Wegovy approved ... by market capitalisation -- confirmed to AFP on Tuesday that Beijing had given the green light for the breakthrough treatment in people ...

Novo Nordisk appealed to the Beijing IP Court (the Court), which reversed CNIPA’s invalidation and upheld the patent. One of the biggest concerns for biopharma patent holders in China has been ...

A series of policy measures are expected to further develop Binhai New Area, a coastal area of Tianjin, and boost coordinated ...

Novo Nordisk's blockbuster drugs Ozempic and Wegovy have slimmed down Hollywood stars and millions of non-celebrities ...

Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when ...

Correspondent Jon Wertheim revisits 60 Minutes' coverage of former mobile giant Nokia and discusses potential risks for the ...

Biopharma Technology Co. Ltd. has led to the identification of Mas-related G-protein coupled receptor member X4 (MRGPRX4; SNSR5; SNSR6) antagonists reported to be useful for the treatment of anemia, ...

COMAC said on Tuesday that Air China would be the launch customer for the Chinese planemaker's C929 widebody aircraft under ...

In a deal worth up to $285 million initially for the lead program, Novo Nordisk will gain access to Ascendis’ TransCon ...

Novo Nordisk is still growing at a high pace and is expanding into new therapeutic areas like Alzheimer's disease, cardiovascular disease, or MASH. But the competition from Eli Lilly increases as ...